XML 62 R50.htm IDEA: XBRL DOCUMENT
v3.26.1

Segment information (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2026
Disclosure of operating segments [abstract] |
Schedule of Segment Results | Segment results are shown in the table below:
| June 30, 2026 (6 months)
(€ million) | Biopharma | Other | Total
| June 30, 2026 | Change vs. June 30, 2025 on a reported basis (IFRS) | Change vs. June 30, 2025 at constant exchange rates (non-IFRS) | June 30, 2026 | Change vs. June 30, 2025 on a reported basis (IFRS) | Change vs. June 30, 2025 at constant exchange rates (non-IFRS) | June 30, 2026 | Change vs. June 30, 2025 on a reported basis (IFRS) | Change vs. June 30, 2025 at constant exchange rates (non-IFRS)
Net sales | 22,106 |  | +11.1 | % | +15.7 | % |  |  |  | 22,106 |  | +11.1 | % | +15.7 | %
Other revenues | 1,168 |  | -6.3 | % | -2.0 | % | 270 |  | +31.1 | % | +31.1 | % | 1,438 |  | -1.0 | % | +2.7 | %
Cost of sales | (5,812) |  | +1.0 | % | +3.8 | % | (133) |  | +3.9 | % | +3.1 | % | (5,945) |  | +1.1 | % | +3.8 | %
Research and development expenses | (3,979) |  | +7.1 | % | +9.9 | % | (1) |  | — | % | — | % | (3,980) |  | +7.1 | % | +9.9 | %
Selling and general expenses | (4,690) |  | +5.5 | % | +9.4 | % | (102) |  | +72.9 | % | +76.3 | % | (4,792) |  | +6.3 | % | +10.3 | %
Other operating income and expenses | (2,630) |  |  |  | (6) |  |  |  | (2,636) |  |  |
Share of profit/(loss) from investments accounted for using the equity method | 74 |  |  |  |  |  |  | 74 |  |  |
Net income attributable to non-controlling interests | (7) |  |  |  |  |  |  | (7) |  |  |
Business operating income | 6,230 |  | +16.5 | % | +22.2 | % | 28 |  | +75.0 | % | +68.8 | % | 6,258 |  | +16.7 | % | +22.3 | %
As % of net sales | 28.2 | % |  |  |  |  |  | 28.3 | % |  |
| June 30, 2025 (6 months)
(€ million) | Biopharma | Other | Total
Net sales | 19,889 |  |  | 19,889 |
Other revenues | 1,246 |  | 206 |  | 1,452 |
Cost of sales | (5,753) |  | (128) |  | (5,881) |
Research and development expenses | (3,716) |  | (1) |  | (3,717) |
Selling and general expenses | (4,447) |  | (59) |  | (4,506) |
Other operating income and expenses | (1,941) |  | (2) |  | (1,943) |
Share of profit/(loss) from investments accounted for using the equity method | 77 |  | — |  | 77 |
Net income attributable to non-controlling interests | (8) |  | — |  | (8) |
Business operating income | 5,347 |  | 16 |  | 5,363 |
Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method | The table below, presented in compliance with IFRS 8, shows a reconciliation between “Business operating income” and Income before tax and investments accounted for using the equity method:
(€ million) | June 30, 2026 (6 months) | June 30, 2025 (6 months) |
Business operating income | 6,258 |  | 5,363 |  |
Share of profit/(loss) from investments accounted for using the equity method (a) | (74) |  | (77) |  |
Net income attributable to non-controlling interests(b) | 7 |  | 8 |  |
Amortization of intangible assets | (1,087) |  | (777) |  |
Impairment of intangible assets(c) | (1,031) |  | (210) |  |
Fair value remeasurement of contingent consideration | (37) |  | (61) |  |
Expense arising from the impact of acquisitions on inventories(d) | (210) |  | — |  |
Restructuring costs and similar items(e) | (563) |  | (430) |  |
Other gains and losses, and litigation(f) | (95) |  | (57) |  |
Operating income | 3,168 |  | 3,759 |  |
Financial expenses | (465) |  | (361) |  |
Financial income | 137 |  | 184 |  |
Income before tax and investments accounted for using the equity method | 2,840 |  | 3,582 |  |
(a)Mainly joint ventures. (b)Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests. (c)The monitoring of impairment indicators for other intangible assets led to the recognition of impairment losses of €1,031 million in the first half of 2026 mainly comprising a €952 million impairment loss taken against the amlitelimab asset. For the six months ended June 30, 2025, this line mainly comprises impairment losses of €210 million linked to research and development projects. (d)This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date, which in the first half of 2026 relate to the Blueprint Medicines and Dynavax acquisitions. (e)See Note B.16. (f)See Note B.17.
Schedule of Acquisition of Intangible Assets, Property, Plant and Equipment and Investments Accounted for Using the Equity Method by Segment | Acquisitions of intangible assets and property, plant and equipment correspond to acquisitions paid for during the period.
| Biopharma
(€ million) | June 30, 2026 | June 30, 2025 |
Investments accounted for using the equity method(a) | 204 |  | 483 |  |
Acquisitions of property, plant and equipment | 882 |  | 845 |  |
Acquisitions of other intangible assets | 414 |  | 575 |  |
(a) Carrying amount at the end of the reporting period.
Summary of Geographical Information on Net Sales and Non-Current Assets | The geographical information on net sales provided below is based on the geographical location of the customer.
| Net sales
(€ million) | June 30, 2026 | June 30, 2025
Europe | 4,304 |  | 4,144 |
of which France | 725 |  | 835 |
United States | 11,633 |  | 9,535 |
Rest of the World | 6,169 |  | 6,210 |
of which China | 1,325 |  | 1,388 |
Total | 22,106 |  | 19,889 |
In accordance with IFRS 8, the non-current assets reported below exclude financial instruments, deferred tax assets, pre-funded pension obligations, and right-of-use assets as determined under IFRS 16.
(€ million) | June 30, 2026 | December 31, 2025
Property, plant and equipment |  |  | Other intangible assets | Property, plant and equipment |  |  | Other intangible assets
Europe | 5,998 |  |  |  | 3,951 |  | 5,760 |  |  |  | 5,094 |
of which France | 3,161 |  |  |  | — |  | 3,123 |  |  |  | — |
United States | 2,270 |  |  |  | 21,972 |  | 2,229 |  |  |  | 20,694 |
Rest of the World | 2,096 |  |  |  | 436 |  | 2,063 |  |  |  | 473 |
of which China | 167 |  |  |  | — |  | 122 |  |  |  | — |
Total | 10,364 |  |  |  | 26,359 |  | 10,052 |  |  |  | 26,261 |

X
- Definition The disclosure of geographical information. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 33 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_33&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfGeographicalAreasExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments. [Refer: Operating segments [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 8 -IssueDate 2025-01-01 -Paragraph 23 -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2025-en-r&anchor=para_23&doctype=Standard -URIDate 2025-03-27 + Details
Name: | ifrs-full_DisclosureOfOperatingSegmentsExplanatory
Namespace Prefix: | ifrs-full_
Data Type: | dtr-2022:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of acquisitions of property plant and equipment and other intangible assets and carrying amount of investments in associates and joint ventures by operating segment. + References No definition available. + Details
Name: | sny_DisclosureOfAcquisitionsOfPropertyPlantAndEquipmentAndOtherIntangibleAssetsAndCarryingAmountOfInvestmentsInAssociatesAndJointVenturesByOperatingSegmentTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition The disclosure of operating segments reconciling items. + References No definition available. + Details
Name: | sny_DisclosureOfOperatingSegmentsReconcilingItemsTableTextBlock
Namespace Prefix: | sny_
Data Type: | dtr-types1:textBlockItemType
Balance Type: | na
Period Type: | duration